Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept"

Mariana P. Miranda-Hernández; Carlos A. López-Morales; Francisco C. Perdomo-Abúndez; Rodolfo D. Salazar-Flores; Nancy D. Ramírez-Ibanez; Nestor O. Pérez; Aaron Molina-Pérez; Jorge Revilla-Beltri; Emilio Medina-Rivero; Luis F. Flores-Ortiz

doi:10.1155/2018/6156024

Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept"

Mariana P. Miranda-Hernández, Carlos A. López-Morales, Francisco C. Perdomo-Abúndez, Rodolfo D. Salazar-Flores, Nancy D. Ramírez-Ibanez, Nestor O. Pérez, Aaron Molina-Pérez, Jorge Revilla-Beltri, Emilio Medina-Rivero, Luis F. Flores-Ortiz

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	6156024
Journal	Journal of Immunology Research
Volume	2018
DOIs	https://doi.org/10.1155/2018/6156024
State	Published - 2018
Externally published	Yes

Access to Document

10.1155/2018/6156024

Cite this

Miranda-Hernández, M. P., López-Morales, C. A., Perdomo-Abúndez, F. C., Salazar-Flores, R. D., Ramírez-Ibanez, N. D., Pérez, N. O., Molina-Pérez, A., Revilla-Beltri, J., Medina-Rivero, E., & Flores-Ortiz, L. F. (2018). Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept". Journal of Immunology Research, 2018, Article 6156024. https://doi.org/10.1155/2018/6156024

@article{d33ffd52e5fe41549314e06d0c57421e,

title = "Response to: Comment on {"}new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept{"}",

author = "Miranda-Hern{\'a}ndez, {Mariana P.} and L{\'o}pez-Morales, {Carlos A.} and Perdomo-Ab{\'u}ndez, {Francisco C.} and Salazar-Flores, {Rodolfo D.} and Ram{\'i}rez-Ibanez, {Nancy D.} and P{\'e}rez, {Nestor O.} and Aaron Molina-P{\'e}rez and Jorge Revilla-Beltri and Emilio Medina-Rivero and Flores-Ortiz, {Luis F.}",

note = "Funding Information: All authors have a strong scientific and proven track record with several refereed publications, patents, and technical conferences. All the authors have accepted responsibility for their contributions, ensuring originality and integrity of the results with data presented according to the journal requirements. Besides, the data was generated upon the use of standardized practices and procedures in Probiomed S.A. de C.V., a pharmaceutical company certified in Good Manufacturing Practices by Mexico{\textquoteright}s Federal Commission for Protection against Sanitary Risks (COFEPRIS), which is recognized as a National Regulatory Authority by the World Health Organization. We therefore found surprising that the scientific integrity of the paper, the reputation of the authors, and the Journal of Immunology Research are questioned.",

year = "2018",

doi = "10.1155/2018/6156024",

language = "Ingl{\'e}s",

volume = "2018",

journal = "Journal of Immunology Research",

issn = "2314-8861",

}

Miranda-Hernández, MP, López-Morales, CA, Perdomo-Abúndez, FC, Salazar-Flores, RD, Ramírez-Ibanez, ND, Pérez, NO, Molina-Pérez, A, Revilla-Beltri, J, Medina-Rivero, E & Flores-Ortiz, LF 2018, 'Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept"', Journal of Immunology Research, vol. 2018, 6156024. https://doi.org/10.1155/2018/6156024

Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept". / Miranda-Hernández, Mariana P.; López-Morales, Carlos A.; Perdomo-Abúndez, Francisco C. et al.
In: Journal of Immunology Research, Vol. 2018, 6156024, 2018.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Response to

T2 - Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept"

AU - Miranda-Hernández, Mariana P.

AU - López-Morales, Carlos A.

AU - Perdomo-Abúndez, Francisco C.

AU - Salazar-Flores, Rodolfo D.

AU - Ramírez-Ibanez, Nancy D.

AU - Pérez, Nestor O.

AU - Molina-Pérez, Aaron

AU - Revilla-Beltri, Jorge

AU - Medina-Rivero, Emilio

AU - Flores-Ortiz, Luis F.

N1 - Funding Information: All authors have a strong scientific and proven track record with several refereed publications, patents, and technical conferences. All the authors have accepted responsibility for their contributions, ensuring originality and integrity of the results with data presented according to the journal requirements. Besides, the data was generated upon the use of standardized practices and procedures in Probiomed S.A. de C.V., a pharmaceutical company certified in Good Manufacturing Practices by Mexico’s Federal Commission for Protection against Sanitary Risks (COFEPRIS), which is recognized as a National Regulatory Authority by the World Health Organization. We therefore found surprising that the scientific integrity of the paper, the reputation of the authors, and the Journal of Immunology Research are questioned.

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85048690782&partnerID=8YFLogxK

U2 - 10.1155/2018/6156024

DO - 10.1155/2018/6156024

M3 - Carta

C2 - 29676408

SN - 2314-8861

VL - 2018

JO - Journal of Immunology Research

JF - Journal of Immunology Research

M1 - 6156024

ER -

Response to: Comment on "new alternatives for autoimmune disease treatments: Physicochemical and clinical comparability of biosimilar etanercept"

Access to Document

Other files and links

Cite this